Bavarian Nordic nabs EU approval for monkeypox vaccine as WHO declares global health emergency
As the WHO declared the monkeypox outbreak to be a global health emergency, Bavarian Nordic obtained an expanded European label for its smallpox vaccine to include the surging virus.
The move comes roughly a month after the biotech filed for a label expansion, and after several countries on the continent, and elsewhere, secured their own supply deals for the shot. Bavarian Nordic has said it’s seen “overwhelming” interest in the vaccine, and its stock price $BVRNY has followed in short order — shares are up 124% since the first monkeypox case was detected on May 6.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
